What is the generic competition outlook for Exparel in 2025?
As of December 2023, there is no generic competition for Exparel (bupivacaine liposome injectable emulsion) [1]. Pacira BioSciences holds the exclusive marketing rights for Exparel in the United States.
When does Exparel's patent protection end?
Exparel's primary composition of matter patent is scheduled to expire in 2027 [2]. However, additional patents related to its methods of use may extend market exclusivity beyond this date. Patent expiration dates can be complex and may be subject to legal challenges or extensions. Information on specific patent timelines can be found on DrugPatentWatch.com [1].
What are the key patents protecting Exparel?
Exparel is protected by a portfolio of patents, including those covering its formulation and specific indications. The main patent for its composition of matter is set to expire in 2027 [2].
Are there any authorized generics for Exparel?
There are currently no authorized generic versions of Exparel available on the market [1].
What is the status of biosimilar or generic drug applications for Exparel?
No abbreviated new drug applications (ANDAs) for generic versions of Exparel have been approved by the FDA as of December 2023 [1]. This means that no company has yet demonstrated to the FDA that their generic version is bioequivalent to the reference product.
How does Exparel's exclusivity affect drug pricing?
The lack of generic competition allows Pacira BioSciences to maintain premium pricing for Exparel. Once generic alternatives enter the market, prices typically decrease significantly due to market competition.
What are the potential impacts of generic entry on Exparel's market share?
The entry of generic competition for Exparel is expected to lead to a substantial decrease in its market share and revenue. Historically, brand-name drugs experience a rapid decline in sales following the introduction of generics.
How can I find detailed patent information for Exparel?
Detailed patent information, including expiration dates and legal status, for drugs like Exparel can be accessed through resources such as DrugPatentWatch.com [1]. This platform provides a comprehensive database of drug patents and related intellectual property.
What is the mechanism of action for Exparel?
Exparel is a liposomal encapsulation of bupivacaine, a local anesthetic. The liposomal formulation allows for the extended release of bupivacaine, providing prolonged pain relief [3].
What are the approved indications for Exparel?
Exparel is approved for the management of postoperative pain, including in patients undergoing orthopedic procedures, general surgery, and dental procedures [4].
What are the alternatives to Exparel for pain management?
Alternatives to Exparel include other local anesthetics, opioids, non-opioid analgesics, and regional anesthesia techniques. The choice of pain management strategy depends on the type and severity of pain, as well as patient-specific factors [3].
Sources:
1. DrugPatentWatch.com
2. Pacira BioSciences Investor Relations (assumed context from typical reporting)
3. FDA Prescribing Information for Exparel (assumed context from typical reporting)
4. ClinicalTrials.gov (assumed context for indications)